Maurits Janssen

Maurits Janssen, Ph.D., Lonza AG - Qepler Summits And Conferences

Maurits Janssen, Ph.D.

Head of Commercial Development, API
Lonza AG
Basel, Switzerland
Lonza is one of the world's leading suppliers to the Pharma&Biotech and Specialty Ingredient markets with products that enhance your overall quality of life.

Maurits Janssen is senior Director, Head of Commercial Development for the Active Pharmaceutical Ingredient (API) Business Unit at Lonza.

Mr. Janssen earned his Ph.D. in organic chemistry from Utrecht University in The Netherlands (1996) and subsequently fulfilled several functions with increasing responsibility in consulting, marketing & sales and research & development.

Mr. Janssen has over 20 year experience in chemical and pharmaceutical industry and over 15 years in the custom manufacturing of active pharmaceutical ingredients.

Throughout his career, Mr. Janssen worked across a broad portfolio of technologies in cGMP Chemical & Biological custom manufacturing from early stage to late phase/commercial and gained significant experience with Highly Potent Active Pharmaceutical Ingredients (HPAPI).

Mr. Janssen will present how a fully integrated service offering can be beneficial to drug developers in achieving their goals for delivering a cost-efficient final product.

Related Sessions:

Qepler - Highly Potent APIs Summit thumbnail Details

Highly Potent APIs
Summit 2019

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 20 Feb 2019
  • Berlin, DE
  • Pharma
Day 1: Wednesday, 20 February 2019
BLOCK: PROCESS ROBUSTNESS, SAFETY & EFFICIENCY.
CASE STUDY: Best practices: requirements for fully-integrated service-offerings in a HPAPI and cytotoxic environment.
  • Drug product development based on potent compounds can be quite challenging.
  • Complications with the interface between operations in drug substance and drug product handling can also result in increased program complexity and cost.
  • In this presentation, we will elaborate on best practices and infrastructure requirements that facilitate accelerated timelines to clinic and market:
    • Development, rapid scaling and commercial production of HPAPI drug substance
    • Integrated containment requirements for particle engineering and drug products
    • Impact of supporting integrated service-offerings on expansion strategies
View Details